Abilitypharma: Ability Pharma closes 2 million round to advance antitumor development

The Spanish company Ability Pharma, specialized in the development of oral anti-cancer compounds, has attracted this funding after receiving a grant of more than $1.19 million (€1 million) from the FDA. With this financial aid, the biopharmaceutical company, based in Cerdanyola del Vallès (Barcelona), will receive more than $10.7 million (€9 million) in private funding this year.